Skip to main content
. 2020 Sep 10;181(1):71–78. doi: 10.1001/jamainternmed.2020.5503

Figure 2. Time to Clinical Improvement at Day 21.

Figure 2.

The blue curve indicates the recombinant human granulocyte colony-stimulating factor (rhG-CSF) group, whereas the orange curve denotes the control group (usual care). The hazard ratio (HR) of achieving clinical improvement, along with the 95% CI and the P value, is also reported. The hazards ratio with the 95% CI was estimated by using the Fine and Gray proportional subdistribution hazards model with treatment group, center, and oxygen therapy being included in the model.